HIGHLIGHTS
- What: The authors report a 42-year-old female with r/r DLBCL who was diagnosed with meningeosis lymphomatosa for the first time six days after receiving CD19 CAR-T_cell therapy with Axicabtagen Ciloleucel.
- Who: Agrippa Hilda from the Universitätsklinikum Würzburg, Würzburg, Germany have published the Article: Successful Treatment of a Relapsed, Refractory Diffuse Large B-, in the Journal: (JOURNAL)
SUMMARY
CD19 targeted CAR-T_cell therapy is a very effective method to treat refractory or relapsed DLBCL with patients achieving nearly 50% complete response rates with that kind . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.